What is the current size of the global generic sterile injectable market?

According to Precedence Research, the generic sterile injectable market was valued at USD 42.39 billion in 2023 is anticipated to reach over USD 108.54 billion by 2033. Read More

What are the factors driving the generic sterile injectable market?

The demand for sterile injectable in the coming years is expected to drive a growing prevalence of chronic diseases, particularly cancer, across the globe. Moreover, the growth of the global industry is also being fuelled by a rising number of drug manufacturers focused on the development of cancer drugs. In addition, rapid FDA sterile injectable drug approvals coupled with shortened approval times for new drug manufacture in cancer treatment are growing the availability of dive drugs and ultimately powering demand in the generic sterile injectable market. Read More

What is the CAGR of global generic sterile injectable market?

The global generic sterile injectable market is growing at a noteworthy CAGR of 9.85% during the forecast period 2024 to 2033. Read More

How much is the market share of North America region in the generic sterile injectable market in 2023?

In year 2023, North America conquered the worldwide market with a market share of greater than 39.05%. Read More

Who are the key players in generic sterile injectable market?

The key companies functioning in the worldwide generic sterile injectable are Baxter, Hikma, Mylan, Fresenius Kabi, Sandoz, Pfizer, Civica, Merck & Co., Inc. Teva, 3M, Nichi-Iko among others. Read More

What is the generic sterile injectable?

The generic sterile injectable refers to the biologics used for the treatment of a variety of medications which includes the same active ingredients found in the marketed versions. Its inactive contents can, however, vary from one another. The generic sterile injectable development process is governed by the U.S. The FDA and its marketed equivalents are similar. U.S. according to National Center for Health Information, it is considered a chronic condition when the disease lasts more than three months within the patient. Chronic diseases are one of the key causes of death, as vaccines and other drugs do not cure them quickly. Read More

Generic Sterile Injectable Market Size, Share, and Trends 2024 to 2034

Generic Sterile Injectable Market (By Product Type: Monoclonal Antibodies, Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulin, Blood Factors, Antibiotics, and Others; By Therapeutic Application: Cancer, Diabetes, Cardiovascular Disease, Central Nervous System, Musculoskeletal System, and Others; By Distribution Channel: Hospitals, Drug Stores, Retail Pharmacies, and Others) - Global Industry Analysis, Market Size, Share, Growth, Trends, Regional Outlook and Forecasts, 2024 - 2033

Last Updated : April 2024
Report Code : 1214
Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Sterile Injectable Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Sterile Injectable Market

5.1. Covid-19: generic sterile injectable Industry Impact
5.2. generic sterile injectable Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and generic sterile injectable Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for generic sterile Injectable Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Sterile Injectable Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. The convenience of sterile injectable in medical treatment boosts the market
6.1.1.2. Development in biotechnology aids rapid investment in injectable
6.1.1.3. Increasing prevalence of chronic illnesses across the globe
6.1.2. Market Restraints
6.1.2.1. High entry barriers due to demanding compliance requirements
6.1.3. Market Opportunities
6.1.3.1. Expiry of patents

Chapter 7. Global Generic Sterile Injectable Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. generic sterile Injectable Market Revenue by Market Players
7.1.1.2. generic sterile Injectable Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Generic Sterile Injectable Market, By Product Type

8.1. generic sterile Injectable Market, by Product Type, 2024-2033
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue Forecast (2021-2033)
8.1.2. Cytokines
8.1.2.1. Market Revenue Forecast (2021-2033)
8.1.3. Insulin
8.1.3.1. Market Revenue Forecast (2021-2033)
8.1.4. Peptide Hormones
8.1.4.1. Market Revenue Forecast (2021-2033)
8.1.5. Vaccines
8.1.5.1. Market Revenue Forecast (2021-2033
8.1.6. Immunoglobulin
8.1.6.1. Market Revenue Forecast (2021-2033)
8.1.7. Blood Factors
8.1.7.1. Market Revenue Forecast (2021-2033)
8.1.8. Antibiotics
8.1.8.1. Market Revenue Forecast (2021-2033)
8.1.9. Others
8.1.9.1. Market Revenue Forecast (2021-2033)

Chapter 9. Global Generic Sterile Injectable Market, By Therapeutic Application

9.1. generic sterile injectable Market, by Therapeutic Application, 2024-2033
9.1.1. Cancer
9.1.1.1. Market Revenue Forecast (2021-2033)
9.1.2. Diabetes
9.1.2.1. Market Revenue Forecast (2021-2033)
9.1.3. Cardiovascular Disease
9.1.3.1. Market Revenue Forecast (2021-2033)
9.1.4. Central Nervous System
9.1.4.1. Market Revenue Forecast (2021-2033)
9.1.5. Musculoskeletal System
9.1.5.1. Market Revenue Forecast (2021-2033)
9.1.6. Others
9.1.6.1. Market Revenue Forecast (2021-2033)

Chapter 10. Global Generic Sterile Injectable Market, By Distribution Channel

10.1. generic sterile injectable Market, by Distribution Channel, 2024-2033
10.1.1. Hospitals
10.1.1.1. Market Revenue Forecast (2021-2033)
10.1.2. Drug Stores
10.1.2.1. Market Revenue Forecast (2021-2033)
10.1.3. Retail Pharmacies
10.1.3.1. Market Revenue Forecast (2021-2033)
10.1.4. Others
10.1.4.1. Market Revenue Forecast (2021-2033)

Chapter 11. Global Generic Sterile Injectable Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Product Type(2021-2033)
11.1.2. Market Revenue Forecast by Therapeutic Application (2021-2033)
11.1.3. Market Revenue Forecast by Distribution Channel (2021-2033)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2021-2033)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2021-2033)
11.2. Europe
11.2.1. Market Revenue Forecast by Product Type (2021-2033)
11.2.2. Market Revenue Forecast by Therapeutic Application (2021-2033)
11.2.3. Market Revenue Forecast by Distribution Channel (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2021-2033)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2021-2033)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Product Type (2021-2033)
11.3.2. Market Revenue Forecast by Therapeutic Application (2021-2033)
11.3.3. Market Revenue Forecast by Distribution Channel (2021-2033)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2021-2033)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2021-2033)
11.4. LATAM
11.4.1. Market Revenue Forecast by Product Type (2021-2033)
11.4.2. Market Revenue Forecast by Therapeutic Application (2021-2033)
11.4.3. Market Revenue Forecast by Distribution Channel (2021-2033)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2021-2033)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2021-2033)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Product Type (2021-2033)
11.5.2. Market Revenue Forecast by Therapeutic Application (2021-2033)
11.5.3. Market Revenue Forecast by Distribution Channel (2021-2033)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2021-2033)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2021-2033)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2021-2033)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2021-2033)

Chapter 12. Company Profiles

12.1. Fresenius Kabi
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Application
12.1.3. Revenue, Price, and Gross Margin (2017-2020)
12.1.4. Recent Developments and Strategies
12.2. Baxter
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Application
12.2.3. Revenue, Price, and Gross Margin (2017-2020)
12.2.4. Recent Developments and Strategies
12.3. Civica
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Application
12.3.3. Revenue, Price, and Gross Margin (2017-2020)
12.3.4. Recent Developments and Strategies
12.4. Pfizer
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Application
12.4.3. Revenue, Price, and Gross Margin (2017-2020)
12.4.4. Recent Developments and Strategies
12.5. Mylan
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Application
12.5.3. Revenue, Price, and Gross Margin (2017-2020)
12.5.4. Recent Developments and Strategies
12.6. Hikma
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Application
12.6.3. Revenue, Price, and Gross Margin (2017-2020)
12.6.4. Recent Developments and Strategies
12.7. Sandoz
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Application
12.7.3. Revenue, Price, and Gross Margin (2017-2020)
12.7.4. Recent Developments and Strategies
12.8. Teva
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Application
12.8.3. Revenue, Price, and Gross Margin (2017-2020)
12.8.4. Recent Developments and Strategies
12.9. Nichi-Iko
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Application
12.9.3. Revenue, Price, and Gross Margin (2017-2020)
12.9.4. Recent Developments and Strategies
12.10. 3M
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Application
12.10.3. Revenue, Price, and Gross Margin (2017-2020)
12.10.4. Recent Developments and Strategies
12.11. Merck & Co., Inc.
12.11.1. Company Overview, Business Information, Regional Presence
12.11.2. Product Portfolio Analysis
12.11.2.1. Product Details, Specification, Application
12.11.3. Revenue, Price, and Gross Margin (2017-2020)
12.11.4. Recent Developments and Strategies

Chapter 13. Appendix

13.1. About Us
13.2. Glossary of Terms

We use cookies to improve your experience

Generic Sterile Injectable Market Size to Hit USD 108.54 Bn by 2033

List of Contents